[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339706-105":59,"doc-detail-339706-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","brcaness-dna-gaps-and-gain-and-loss-of-parp-inhibitorinduced-synthetic-lethality","BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality","","BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality review explains why PARP inhibitors effectively target BRCA1/2-deficient cancers yet fail in many patients and commonly drive acquired resistance. It summarizes evidence that functional defects in BRCA1/2-deficient cells—especially defects affecting suppression and protection of single-stranded DNA gaps—can determine gain or loss of PARPi-induced synthetic lethality. The article connects mechanistic changes to revised models and emerging principles for predicting PARPi response and guiding therapy design to overcome resistance.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/brcaness-dna-gaps-and-gain-and-loss-of-parp-inhibitorinduced-synthetic-lethality/339706/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/brcaness-dna-gaps-and-gain-and-loss-of-parp-inhibitorinduced-synthetic-lethality/339706.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"How does the review frame PARPi mechanism and therapy implications?","Question",{"text":113,"@type":114},"It discusses updated mechanistic models explaining PARPi selectivity in BRCA-deficient cells and outlines emerging principles for predicting PARPi sensitivity and designing strategies to overcome resistance.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},339706,1790648841,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":132,"language":133,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":134,"faqs":135,"seo_title":136,"seo_description":67,"update_tm":137,"read_time":41,"preview_page_count":19,"preview_urls":138},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Clinical Investigation REVIEW  \nBRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality  \nXin Li and Lee Zou  \nDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA.  \nMutations in the tumor-suppressor genes BRCA1 and BRCA2 resulting in BRCA1/2 deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other cancers. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cancer cells by inducing synthetic lethality, providing an effective biomarker-guided strategy for targeted cancer therapy. However, a substantial fraction of cancer patients carrying BRCA1/2 mutations do not respond to PARPis, and most patients develop resistance to PARPis over time, highlighting a major obstacle to PARPi therapy in the clinic. Recent studies have revealed that changes of specific functional defects of BRCA1/2-deficient cells, particularly their defects in suppressing and protecting single-stranded DNA gaps, contribute to the gain or loss of PARPi-induced synthetic lethality. These findings not only shed light on the mechanism of action of PARPis, but also lead to revised models that explain how PARPis selectively kill BRCA-deficient cancer cells. Furthermore, new mechanistic principles of PARPi sensitivity and resistance have emerged from these studies, generating potentially useful guidelines for predicting the PARPi response and design therapies for overcoming PARPi resistance. In this Review, we will discuss these recent studies and put them in context with the classic views of PARPi-induced synthetic lethality, aiming to stimulate the development of new therapeutic strategies to overcome PARPi resistance and improve PARPi therapy.  \nThe concepts of synthetic lethality and BRCAness  \nThe concept of synthetic lethality was first described by the fly geneticist Calvin Bridges in 1922 (1, 2) as the combination of two genetic events that results in cell death or death of an organism. The term “synthetic lethality” is commonly used to describe a specific type of genetic interaction whereby simultaneous loss of two nonessential functions is incompatible with cell or organismal viability. Since its conception, synthetic lethality has been widely used by genetic studies in different model organisms to help with understanding the functional relationships between different genes and pathways. During the last two decades, the concept of synthetic lethality has been successfully applied to cancer therapy, allowing us to exploit various vulnerabilities of cancer cells (3). The basic rationale for this approach is that the oncogenic events in cancer cells give rise to distinct vulnerabilities, rendering cancer cells more dependent on certain genes and pathways for survival than normal cells. When the functions of these genes and pathways are disrupted, selective or preferential killing of cancer cells can be achieved. Thus, the synthetic lethality of cancer cells in a therapeutic setting is not an effect of two incompatible genetic events, but a result of a targeted drug exploiting a liability in a specific oncogenic context. A classic example of the use of synthetic lethality in cancer therapy  \nConflict of interest: LZ is a cofounder of Sirrona Therapeutics and received research support from Pfizer and Bristol Myers Squibb.  \nCopyright: © 2024, Li et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nReference information: J Clin Invest. 2024;134(14):e181062 .  \n[https://doi.org/10.1172/JCI181062](https://doi.org/10.1172/JCI181062) .  \nis the development of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancer patients carrying mutations in BRCA1/2 tumor-suppressor genes (3). As we will discuss below, the loss of BRCA1/2 functions in cancer cells creates a dependency upon proper PARP functions and cyc","cbCaij57aDMIkm2l","https://ap.wps.com/l/cbCaij57aDMIkm2l","pdf",765349,12,"English","# The concepts of synthetic lethality and BRCAness\n## A classic example of synthetic lethality in cancer therapy\n## BRCA1 and BRCA2 functions and genomic protection","[{\"question\":\"How does the review frame PARPi mechanism and therapy implications?\",\"answer\":\"It discusses updated mechanistic models explaining PARPi selectivity in BRCA-deficient cells and outlines emerging principles for predicting PARPi sensitivity and designing strategies to overcome resistance.\"}]","BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality | PDF",1790031734,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61184ea8593220ba9d58aa127b3c14ac.webp",983,1315,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f84773fdf1ca3b3e5f87a60503653a1.webp",982,1314,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c71796f6e7435754dfaa9b7b96ca5142.webp",981,1312,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82fe1dbcdfaeafd59761252b2074215d.webp",980,1311]